Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates

Artursson, 2001, Caco-2 monolayers in experimental and theoretical predictions of drug transport, Adv Drug Deliv Rev, 46, 27, 10.1016/S0169-409X(00)00128-9 Irvine, 1999, MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening, J Pharm Sci, 88, 28, 10.1021/js9803205 Houston, 1997, Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices, Drug Metab Rev, 29, 891, 10.3109/03602539709002237 Shibata, 2002, Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method, Drug Metab Dispos, 30, 892, 10.1124/dmd.30.8.892 Gertz, 2010, Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data, Drug Metab Dispos, 38, 1147, 10.1124/dmd.110.032649 Nishimuta, 2011, Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data, Drug Metab Pharmacokinet, 26, 592, 10.2133/dmpk.DMPK-11-RG-034 Kadono, 2010, Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor, Drug Metab Dispos, 38, 1230, 10.1124/dmd.109.029322 Kato, 2003, The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature, Drug Metab Pharmacokinet, 18, 365, 10.2133/dmpk.18.365 Yang, 2007, Prediction of intestinal first-pass drug metabolism, Curr Drug Metab, 8, 676, 10.2174/138920007782109733 Crespi, 1996, Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4, Pharm Res, 13, 1635, 10.1023/A:1016428304366 Brimer, 2000, Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein, Pharm Res, 17, 803, 10.1023/A:1007599923694 Kataoka, 2013, Establishment of MDCKII cell monolayer with metabolic activity by CYP3A4 transduced with recombinant adenovirus, Drug Metab Pharmacokinet, 125, 10.2133/dmpk.DMPK-12-RG-059 Schmiedlin-Ren, 1997, Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3, Mol Pharmacol, 51, 741, 10.1124/mol.51.5.741 Fisher, 1999, First-pass midazolam metabolism catalyzed by 1alpha, 25-dihydroxy vitamin D3-modified Caco-2 cell monolayers, J Pharmacol Exp Ther, 289, 1134 Hu, 1999, Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase, Pharm Res, 16, 1352, 10.1023/A:1018986605929 Kazuki, 2011, Refined human artificial chromosome vectors for gene therapy and animal transgenesis, Gene Ther, 18, 384, 10.1038/gt.2010.147 Kazuki, 2011, Human artificial chromosomes for gene delivery and the development of animal models. Molecular therapy, J Am Soc Gene Ther, 19, 1591 Hiratsuka, 2011, Integration-free iPS cells engineered using human artificial chromosome vectors, PLoS One, 6, e25961, 10.1371/journal.pone.0025961 Guengerich, 2009, Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase, Nat Protoc, 4, 1245, 10.1038/nprot.2009.121 Cummins, 2004, CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam, J Pharmacol Exp Ther, 308, 143, 10.1124/jpet.103.058065 Wacher, 1995, Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy, Mol Carcinog, 13, 129, 10.1002/mc.2940130302 Lin, 2002, Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism, Mol Pharmacol, 62, 162, 10.1124/mol.62.1.162 Fisher, 1999, Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding, J Pharmacol Exp Ther, 289, 1143 Cummins, 2001, Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, Pharm Res, 18, 1102, 10.1023/A:1010914624111 Sugano, 2002, Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model, Int J Pharm, 241, 241, 10.1016/S0378-5173(02)00240-5